Acumen (ABOS) Pharmaceuticals presented extended results from its validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, showing this strategy has performed as intended. The company presented the results during an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD, in Vienna, Austria, from April 1-5, 2025, and will deliver an encore presentation at the American Academy of Neurology. AAN, Annual Meeting in San Diego, Calif., from April 5-9, 2025. Acumen is also presenting posters on methods of interrogating the binding of AbetaOs to a model of human neurons, methods to advance Abeta selectivity measurements and early effects of sabirnetug on synaptic biomarkers in AD.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges
- Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target
- Acumen price target lowered to $11 from $15 at H.C. Wainwright
- Acumen price target lowered to $10 from $12 at BofA
- Acumen price target lowered to $4 from $6 at UBS